Robert Bruce Montgomery MD

Oncology•Seattle, WA

Professor, Medicine, University of Washington School of Medicine

Join to View Full Profile

1959 Ne Pacific StBox 356158Seattle, WA 98195
Phone+1 206-598-0860

Clinical Expertise

General medical oncology, Hematologic oncology, Urethral cancer

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1990 - 1993
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1987 - 1990
Duke University School of MedicineClass of 1987

Certifications & Licensure

WA State Medical License 1990 - 2027
American Board of Internal Medicine Medical Oncology

Clinical Trials

Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer Start of enrollment: 2005 Mar 01
Completed
Phase 2
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
RECRUITING
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Completed
Phase 2
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2013 May 01
Completed
Not Applicable
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 1, Phase 2
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers Start of enrollment: 2021 Aug 31
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss Start of enrollment: 2024 May 31
RECRUITING
PHASE2
Roles: Contact
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer Start of enrollment: 2019 Oct 01
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes afterLu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous R...
Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, Ali T Arafa, Laura S Graham
European Urology Oncology. 2025-02-06
2 citations
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who ReceivedLu-PSMA-617: Importance ofF-FDG-...
Ridvan Arda Demirci, Alireza Ghodsi, Roman Gulati, Sanaz Behnia, Peter S Nelson
Journal of Nuclear Medicine. 2025-01-03
2 citations
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer ReceivingLu-PSMA-617.
Ridvan Arda Demirci, Roman Gulati, Jessica E Hawley, Todd Yezefski, Michael C Haffner
Journal of Nuclear Medicine. 2024-12-03

Press Mentions

Open Clinical Trials for Patients with Prostate CancerMarch 10th, 2025
Genetic Risk Scores and Prostate CancerJanuary 6th, 2025
What the Future Holds for Traveling NursesAugust 22nd, 2023

Professional Memberships

American Society of Clinical Oncology - ASCO
Member